Latest period
$70.50M
YoY change
-6405.1%
5Y CAGR
—
Peak year (2025)
$524.08M
Latest annual
$524.08M
Operating Cash Flow history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: $524.08M
Operating Cash Flow growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: -6405.1%
Operating Cash Flow history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| 2025 | $524.08M | -6405.1% | +$532.39M | ||
| 2024 | −$8.31M | -108.0% | −$112.47M | ||
| 2023 | $104.16M | -119.2% | +$645.43M | ||
| 2022 | −$541.27M | -15.6% | +$100.42M | ||
| 2021 | −$641.69M | +4.3% | −$26.73M | ||
| 2020 | −$614.96M | +120.9% | −$336.53M | ||
| 2019 | −$278.43M | -50.5% | +$284.19M | ||
| 2018 | −$562.62M | +47.0% | −$179.83M | ||
| 2017 | −$382.79M | +24.4% | −$75.08M | ||
| 2016 | −$307.70M | +62.7% | −$118.56M | ||
| 2015 | −$189.14M | +14.2% | −$23.50M | ||
| 2014 | −$165.64M | +141.3% | −$96.98M | ||
| 2013 | −$68.66M | -40.6% | +$46.95M | ||
| 2012 | −$115.61M | +32.8% | −$28.54M | ||
| 2011 | −$87.07M | +3.2% | −$2.73M | ||
| 2010 | −$84.34M | +16.9% | −$12.20M | ||
| 2009 | −$72.14M | -210.2% | −$137.64M | ||
| 2008 | $65.49M | -66.7% | −$131.03M | ||
| 2007 | $196.52M | -897.9% | +$221.15M | ||
| 2006 | −$24.63M | +49.4% | −$8.14M | ||
| 2005 | −$16.48M | -15.8% | +$3.08M | ||
| 2004 | −$19.57M | +52.6% | −$6.74M | ||
| 2003 | −$12.83M | +903.8% | −$11.55M | ||
| 2002 | −$1.28M | — | — |
- 2025$524.08M-6405.1%
- 2024−$8.31M-108.0%
- 2023$104.16M-119.2%
- 2022−$541.27M-15.6%
- 2021−$641.69M+4.3%
- 2020−$614.96M+120.9%
- 2019−$278.43M-50.5%
- 2018−$562.62M+47.0%
- 2017−$382.79M+24.4%
- 2016−$307.70M+62.7%
- 2015−$189.14M+14.2%
- 2014−$165.64M+141.3%
- 2013−$68.66M-40.6%
- 2012−$115.61M+32.8%
- 2011−$87.07M+3.2%
- 2010−$84.34M+16.9%
- 2009−$72.14M-210.2%
- 2008$65.49M-66.7%
- 2007$196.52M-897.9%
- 2006−$24.63M+49.4%
- 2005−$16.48M-15.8%
- 2004−$19.57M+52.6%
- 2003−$12.83M+903.8%
- 2002−$1.28M—
Operating Cash Flow values are taken from Alnylam Pharmaceuticals's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at Alnylam Pharmaceuticals (ALNY)
Operating Cash Flow for Alnylam Pharmaceuticals (ALNY): headline value $70.50M · YoY -6405.1%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Alnylam Pharmaceuticals (ALNY) most recent annual operating cash flow stands at $524.08M (2025) – plunged 6405.1% year-over-year.
Across the available history, operating cash flow reached its high of $524.08M in 2025 and its low of −$641.69M in 2021.
Alnylam Pharmaceuticals Operating Cash Flow by Year
Alnylam Pharmaceuticals Operating Cash Flow 2025: $524.08M
2025's operating cash flow for Alnylam Pharmaceuticals came in at $524.08M, plunged 6405.1% below 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Operating Cash Flow 2024: −$8.31M
Alnylam Pharmaceuticals posted operating cash flow of −$8.31M in 2024, plunged 108.0% below 2023.
Alnylam Pharmaceuticals Operating Cash Flow 2023: $104.16M
In 2023, Alnylam Pharmaceuticals reported operating cash flow of $104.16M, plunged 119.2% below 2022.
Alnylam Pharmaceuticals Operating Cash Flow 2022: −$541.27M
Alnylam Pharmaceuticals operating cash flow in 2022 was −$541.27M, declined 15.6% below 2021.
Alnylam Pharmaceuticals Operating Cash Flow 2021: −$641.69M
Alnylam Pharmaceuticals operating cash flow in 2021 was −$641.69M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Operating Cash Flow
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation